Characteristics | Training set (n = 494) | Validation set 1 (n = 226) | Validation set 2 (n = 398) | |||
---|---|---|---|---|---|---|
Number of cases | % | Number of cases | % | Number of cases | % | |
Median | 66 (33–88) |  | 61 (30–76) |  | 70 (38–89) |  |
Age (years) | ||||||
 ≥ 65 | 274 | 55.5 | 62 | 27.4 | 291 | 73.1 |
 < 65 | 220 | 44.5 | 164 | 72.6 | 107 | 26.9 |
Gender | ||||||
 Male | 228 | 46.2 | 105 | 46.5 | 176 | 44.2 |
 Female | 266 | 53.8 | 121 | 53.5 | 222 | 55.8 |
Stage | ||||||
 Stage 3–4 | 106 | 21.8 | 0 | 0 | 72 | 18.3 |
 Stage 1–2 | 380 | 78.2 | 226 | 100 | 321 | 81.7 |
Smoking | ||||||
 Yes | 411 | 85.6 | 111 | 49.1 | 300 | 90.6 |
 No | 69 | 14.4 | 115 | 50.9 | 31 | 9.4 |
KRAS mutation | ||||||
 Mutation |  |  | 20 | 8.8 | 139 | 34.9 |
 Wild-type |  |  | 206 | 91.1 | 259 | 65.1 |
EGFR mutation | ||||||
 Mutation |  |  | 127 | 56.2 | 41 | 10.3 |
 Wild-type |  |  | 99 | 43.8 | 357 | 89.7 |
T | ||||||
 T 3–4 | 64 | 13 |  |  |  |  |
 T 1–2 | 427 | 87 |  |  |  |  |
M | ||||||
 Positive | 25 | 7.1 |  |  |  |  |
 Negative | 325 | 92.9 |  |  |  |  |
N | ||||||
 Positive | 164 | 34 |  |  |  |  |
 Negative | 318 | 66 |  |  |  |  |